Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30727333 | 1.00 | TSHR (0.49) | TSHRTDP1KMT2AMEN1NPC1 | |
| SCHEMBL9097438 | 0.89 | MEN1 (0.50) | TSHRTDP1KMT2AMEN1NPC1 | |
| SCHEMBL5925504 | 0.88 | MAPT (0.55) | TDP1KMT2AMEN1ALDH1A1PKM | |
| SCHEMBL1185312 | 0.86 | TDP1 (0.57) | TDP1KMT2AMEN1ALDH1A1PKM | |
| SCHEMBL5642158 | 0.85 | RAB9A (0.45) | TSHRTDP1KMT2AMEN1NPC1 | |
| SCHEMBL7526257 | 0.85 | CHRNB2 (0.45) | TSHRTDP1KMT2AMEN1NPC1 | |
| SCHEMBL23754428 | 0.84 | PTGS2 (0.55) | TDP1KMT2AMEN1ALDH1A1PKM | |
| SCHEMBL13605636 | 0.84 | L3MBTL1 (0.53) | TSHRKMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL7517952 | 0.83 | ADRB2 (0.41) | TSHRTDP1KMT2AMEN1NPC1 | |
| SCHEMBL10229402 | 0.83 | RAB9A (0.46) | TSHRTDP1KMT2AMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353862-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2025-11-20 | — | — | US | disclosed |
| EP-4547671-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | Anima Biotech Inc. (US) | 2025-05-07 | — | — | EP | disclosed |
| WO-2024010761-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| US-20110052492-A1 | Radiohalogenated Benzamide Derivatives And Their Use In Tumor Diagnosis And Tumor Therapy | FRIEBE MATTHIAS | 2011-03-03 | — | — | US | disclosed |
| US-20110027179-A1 | Radiohalogenated Benzamide Derivatives And Their Use In Tumor Diagnosis And Tumor Therapy | FRIEBE MATTHIAS | 2011-02-03 | — | — | US | disclosed |
| US-7850948-B2 | Radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy | BAYER SCHERING PHARMA AG (DE) | 2010-12-14 | — | — | US | disclosed |
| US-20090012090-A1 | Radiohalogenated Benzamide Derivatives And Their Use In Tumor Diagnosis And Tumor Therapy | FRIEBE MATTHIAS | 2009-01-08 | — | — | US | disclosed |
| US-7427390-B2 | Radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy | SCHERING AG (DE) | 2008-09-23 | — | — | US | disclosed |
| EP-1722827-A2 | RADIOHALOGENATED BENZAMIDE DERIVATIVES AND THEIR USE IN TUMOR DIAGNOSIS AND TUMOR THERAPY | Schering AG (DE) | 2006-11-22 | — | — | EP | disclosed |
| WO-2005089815-A2 | RADIOHALOGENATED BENZAMIDE DERIVATIVES AND THEIR USE IN TUMOR DIAGNOSIS AND TUMOR THERAPY | SCHERING AG (DE) | 2005-09-29 | — | — | WO | disclosed |
| US-20050207972-A1 | Radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-09-22 | — | — | US | disclosed |
| EP-1173414-A1 | N-PROTECTED AMINES AND THEIR USE AS PRODRUGS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000064864-A9 | N-PROTECTED AMINES AND THEIR USE AS PRODRUGS | CANCER RES CAMPAIGN TECH (GB) | 2001-12-27 | — | — | WO | disclosed |
| WO-2000064864-A1 | N-PROTECTED AMINES AND THEIR USE AS PRODRUGS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2000-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110027179-A1 | Radiohalogenated Benzamide Derivatives And Their Use In Tumor Diagnosis And Tumor Therapy | BRDT, AADAC, IDH2 | TSHR 870/4885TDP1 3195/4885KMT2A 517/4885 |
| US-20090012090-A1 | Radiohalogenated Benzamide Derivatives And Their Use In Tumor Diagnosis And Tumor Therapy | BRDT, AADAC, IDH2 | TSHR 870/4885TDP1 3195/4885KMT2A 517/4885 |
| US-20250353862-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | MYC, MYCBP, MYCBP2 | TSHR 3934/4885TDP1 3333/4885KMT2A 1391/4885 |
| US-20110052492-A1 | Radiohalogenated Benzamide Derivatives And Their Use In Tumor Diagnosis And Tumor Therapy | BRDT, AADAC, IDH2 | TSHR 870/4885TDP1 3195/4885KMT2A 517/4885 |
| US-20050207972-A1 | Radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy | BRDT, AADAC, IDH2 | TSHR 870/4885TDP1 3195/4885KMT2A 517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.